Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.71 |
| ▸ | HTR3B | O95264 | 4/20 | 0.71 |
| ▸ | HTR3A | P46098 | 4/20 | 0.71 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.71 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.71 |
| ▸ | HTR2C | P28335 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HTR1D | P28221 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.62 |
| ▸ | HTR7 | P34969 | 6/20 | 0.57 |
| ▸ | HTR1A | P08908 | 5/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844125 | 0.87 | HTR3E (0.77) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL13344817 | 0.87 | HTR3E (0.67) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3849165 | 0.85 | HTR3E (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL12017183 | 0.84 | ALDH1A1 (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL231692 | 0.83 | ALDH1A1 (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6094745 | 0.83 | ALDH1A1 (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL17103066 | 0.83 | HTR3E (0.71) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL271333 | 0.82 | PRMT6 (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18210659 | 0.82 | PRMT6 (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4286935 | 0.82 | ADRB1 (0.67) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | HTR3E 836/4885HTR3B 660/4885HTR3A 916/4885 |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | HTR3E 945/4885HTR3B 587/4885HTR3A 1006/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | HTR3E 1287/4885HTR3B 814/4885HTR3A 1292/4885 |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | WEE1, WEE2, PEAK1 | HTR3E 2816/4885HTR3B 4548/4885HTR3A 4217/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | HTR3E 879/4885HTR3B 1110/4885HTR3A 1106/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | HTR3E 1287/4885HTR3B 814/4885HTR3A 1292/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | HTR3E 1287/4885HTR3B 814/4885HTR3A 1292/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | HTR3E 3199/4885HTR3B 2387/4885HTR3A 3635/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | HTR3E 1287/4885HTR3B 814/4885HTR3A 1292/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | HTR3E 2867/4885HTR3B 1551/4885HTR3A 2526/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | HTR3E 1191/4885HTR3B 749/4885HTR3A 1213/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | HTR3E 4086/4885HTR3B 4081/4885HTR3A 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.